PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer
Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.
Stay updated with breaking news from Urologic Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.
With AI, Dr. Artem Cherkasov and researchers took 19 days not 10 years to review 40 billion compounds to find potential COVID-19 drugs
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Article content Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium – Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsore...
(2) Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ("Amp B Tech" or the "Company"), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ("iCo"), announced today that two presentations related to research on the effectiveness of the Company's Oral Amphotericin B formulation ("iCo 019") on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium - Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharma...